1 results match your criteria: "Xi'an PLA 451 Hospital[Affiliation]"
Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.
Cancer Res
January 2015
Department of Medical Imaging, Xi'an PLA 451 Hospital, Xi'an, Shaanxi, P. R. China. Department of Interventional Oncology, Xi'an PLA 451 Hospital, Xi'an, Shaanxi, P. R. China.
Article Synopsis
- Multiple anti-HER receptor antibodies like cetuximab, trastuzumab, and pertuzumab are common treatments for metastatic cancer, but drug resistance often arises due to HER-MET crosstalk.
- The study developed two new tetra-specific antibodies, FL518 and CRTB6, that target EGFR, HER2, HER3, and VEGF, effectively disrupting HER-MET interactions.
- These new tetra-specific antibodies demonstrated superior efficacy against anti-HER-resistant cancer cells compared to traditional bispecific antibodies, suggesting a novel approach to overcoming drug resistance.